PMS-QUINAPRIL 20 MG
QUINAPRIL (QUINAPRIL HYDROCHLORIDE) : 20 MG · DIN 02340577 · PHARMASCIENCE INC
Health Canada status: MARKETED
What is PMS-QUINAPRIL?
PMS-QUINAPRIL 20 MG contains QUINAPRIL (QUINAPRIL HYDROCHLORIDE) : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02340577, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Nov-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-QUINAPRIL used for?
Treatment of essential hypertension and congestive heart failure (as adjunctive therapy to diuretics and/or digitalis glycosides).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02340577 |
|---|---|
| Brand name | PMS-QUINAPRIL |
| Generic / active ingredient | QUINAPRIL (QUINAPRIL HYDROCHLORIDE) : 20 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 20 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09AA06 QUINAPRIL |
| AHFS class | 24:32.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Nov-2013 |
| Original market date | 2013-11-18 00:00:00 |
How is it administered?
Hypertension: Initial 10-20 mg once daily (5 mg if on diuretics). CHF: Initial 5 mg once daily. Titrate based on response. Max 40 mg/day. Administer on non-dialysis days in hemodialysis patients.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (standard practice is 15-30°C, but field is null based on provided text).
How is it supplied?
Bottles of 100 and 500 tablets.
Contraindications
Hypersensitivity to quinapril or ACE inhibitors; history of angioedema; pregnancy/nursing; use with sacubitril/valsartan, aliskiren, or ARBs in specific patients (e.g., diabetes, renal impairment).
Warnings and precautions
Risk of angioedema (head/neck/intestinal); hypotension (especially volume/salt depleted patients); hyperkalemia; neutropenia/agranulocytosis; impaired liver function; dual blockade of RAS.
What can be used instead?
Other Canadian products sharing ATC code C09AA06 QUINAPRIL. 6 of 32 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP QUINAPRIL | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02517450 |
| JAMP QUINAPRIL | 20 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02517469 |
| JAMP QUINAPRIL | 40 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02517477 |
| PMS-QUINAPRIL | 10 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02340569 |
| PMS-QUINAPRIL | 40 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02340585 |
| ACCUPRIL 5MG TAB | 5 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 01947664 |
| ACCUPRIL TAB 10MG | 10 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 01947672 |
| ACCUPRIL TAB 20MG | 20 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 01947680 |
| ACCUPRIL TAB 40MG | 40 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 01947699 |
| APO-QUINAPRIL | 10 MG | TABLET | APOTEX INC | DORMANT | DIN 02248500 |
Who else supplies QUINAPRIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. QUINAPRIL appears in 23 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.